MedPath

Revotar Biopharmaceuticals AG

🇩🇪Germany
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:3
Completed:3

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (100.0%)

Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: Placebo
First Posted Date
2010-04-22
Last Posted Date
2011-05-09
Lead Sponsor
Revotar Biopharmaceuticals AG
Target Recruit Count
60
Registration Number
NCT01108913
Locations
🇩🇪

Insaf - Respiratory Research Institute GmbH, Wiesbaden, Germany

Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Drug: Placebo
First Posted Date
2009-08-20
Last Posted Date
2010-01-06
Lead Sponsor
Revotar Biopharmaceuticals AG
Target Recruit Count
18
Registration Number
NCT00962481
Locations
🇩🇪

Pneumologisches Forschungsinstitut GmbH am Krankenhaus Großhansdorf, Großhansdorf, Germany

Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo Cream
First Posted Date
2009-01-16
Last Posted Date
2009-08-21
Lead Sponsor
Revotar Biopharmaceuticals AG
Target Recruit Count
107
Registration Number
NCT00823693
Locations
🇩🇪

Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany

News

No news found
© Copyright 2025. All Rights Reserved by MedPath